KNOWLEDGE BANK

Interviews

Powder Systems Limited

Tendering Manager Asia-Pacific
Powder Systems Limited PSL has been exporting its technology to the AsiaPacific market since and a growing number of turnkey installations are to be commissioned in this region in the future To support the demand PSL has committed to further investment in AsiaPacific APAC by opening an engineering and sales office in Singapore This addition to PSL APAC will reinforce the fast growing activities c...

Articles

AI Cures

Ever wondered why the specter of infectious diseases like COVID still haunts us despite decades of medical advancements The answer lies in the escalating threat of antimicrobial resistance

Research Insights

Drug-related Stigma Among People Who Inject Drugs – Development and Validation of the Drug Use Stigma Scale (DUSS)

Drug use is a highly stigmatized behavior and drugrelated stigma is a key driver of behavioral risk lower health care utilization and associated adverse health outcomes among people who inject drugs PWID

Case Studies

Open Innovation in Pharmaceutical Industry: A Case Study by Eli Lilly

Abstract Interest on Open Innovation paradigm has seen a phenomenal increase since last two decades especially when Henry Chesbrough coined this term in triggering the creation of a new whole body of knowledge However all of his research work could not come up with a standardized allinone theory Instead we find a heterogeneous series of models tha

Techno Trends

First-of-its-kind Clinical Trial Monitoring Service Launched for Cancer Patients

Specimatch the first continual clinical trial monitoring service announces the launch of its webbased software service for cancer patients Users can easily connect to clinical trials personally matched to the patients genetic and clinical profiles through Specimatchcom This software is a solution for patients and oncologists to tap into a complex landscape of break...

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Untapped Opportunities in Southeast Asia

Sue Lee

Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.

2

The Role of Bioinformatics in Accelerating Translational Research

Vasundhara Dauneria

Vasundhara Dauneria is a biotechnology professional with over six years of experience spanning genomics, next-generation sequencing, and bioinformatics. She has worked across wet-lab and computational research environments, with hands-on expertise in NGS workflows, assay development, and multi-omics data analysis. Her work focuses on applying data-driven approaches to support translational research and precision medicine initiatives.

3

CAR-T Cell Therapy and NexCAR19

Ashwini Kumar

Dr Ashwini Kumar is presently working as an Assistant Professor in the Biotechnology and Bioinformatics Area at NIIT University, Neemrana (Rajasthan), India. Biomaterial science has been the main focus of Ashwini's research, particularly in the area of cutting-edge drug delivery techniques. His research's intended uses are developing minimally invasive and non-invasive medication delivery strategies to improve patient compliance and outcomes. Two other area that pique his curiosity are tissue engineering and diabetes. Ashwini is the author for twenty-two journal articles published in both domestic and foreign journals, eight book chapters, a book. In addition, he has a patent for his PhD work. He has been asked to participate in juries and speak on several national scientific venues. He has been working as a reviewer for reputable journals published by Frontiers, Elsevier, and Wiley. He is a guest editor of Frontiers in Medical Technology, a focused journal from Frontiers Publications, and a regular reviewer of Materials and Design, Elsevier. He is a life member of Asian Polymer Association.

 

4

3D Printing

Stéphane Roulon

Stéphane Roulon is a pharmaceutical entrepreneur with over ten years of experience in developing 3D printing technologies for drug manufacturing. He is the CEO of MB Therapeutics, a pharmaceutical establishment specializing in personalized medicines produced using advanced 3D printing solutions to support the future of precision medicine.

5

Precision medicine for Alzheimer’s Disease

Dr. Parmi Tripathi

Dr Parmi is a scientific researcher and an expert medical writer with Ph.D specialising in neurosciences. With an extensive pharmaceutical and healthcare industry experience, she excels at driving innovation. Focused at patient’s centricity, she has played key role in developing innovative medicines that makes meaningful impact on patient’s lives. Dr Parmi has made significant contribution at establishing a patented mouth-dissolving strip (MDS) manufacturing facility. With proven expertise in novel product development, her strong emphasis on quality manufacturing has led to structuring of quality documentation practices for this novel & patented MDS technology aligned with regulatory standards.

Dr Parmi has made significant contributions in field of neuroscience research with multiple acclaimed publications. A distinguished medical writer, she serves as editorial board member and peer reviewer in prestigious journals and continuous to make an impact in her field. Author at reputed public health platform, she writes to promote health awareness. Recognised for her exceptional contributions, she is a multiple-time government R&D grant recipient, particularly in neurodegenerative disorder studies.

press releasesRead more...

Beyond Annex 1: PDA Aseptic Processing of Biopharmaceuticals Conference 2026 Explores the Future of Sterility Assurance

The Parenteral Drug Association PDA Asia Pacific will host the PDA Aseptic Processing of Biopharmaceuticals Conference on November at the Sheraton Grand Incheon Hotel in Incheon South Korea

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

AstraZenecas ETCAMAH camizestrant in combination with a cyclindependent kinase CDK inhibitor abemaciclib palbociclib or ribociclib has been approved in the US for the treatment of adult patients

Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026

As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders

Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform

Integrated DNA Technologies IDT a Danaher company and a global leader in genomics and Ansa Biotechnologies Inc a trusted partner for DNA synthesis today announced an expansion of their partnership

Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience

Biocytogen Pharmaceuticals Beijing Co Ltd Biocytogen SSE HKEX today announced that it has entered into a nonexclusive licensing agreement with Qilu Pharmaceutical Co Ltd

Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Heidelberg Pharma AG FSE HPHA a clinicalstage biotech company developing innovative Antibody Drug Conjugates ADCs today announced that its whollyowned subsidiary Heidelberg Pharma Research

EventsRead more...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease

Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients

Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026

As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders

HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy

HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPLA an investigational antibodytargeted therapy conjugate ATTC designed to target KRAS and EGFR in solid tumours

Everest Medicines Receives Approval for CARDAMYST to Treat Acute PSVT

Everest Medicines has received approval from Chinas National Medical Products Administration NMPA for CARDAMYST etripamil nasal spray for the conversion of acute symptomatic episodes

HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy

Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine

Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains